Oxcarbazepine Tablet, Film Coated
Product Images NDC 70518-2253

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 70518-2253). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxcarbazepine 150mg 70518 2253 01

OXcarbazepine 150 mg film-coated tablets packaging label showing the quantity of 100 tablets. The label includes the product NDC number 70518-2253-01, manufacturer information (Breckenridge, Boca Raton, FL), and repackaging by RemedyRepack Inc. It includes usage directions note to see package insert and storage temperature recommendations. The label also features a QR code and cautions to keep medicine out of reach of children.*

FDA Label Image

Oxcarbazepine 150mg 70518 2253 02

OXcarbazepine 150 mg oral film-coated tablet label. The label indicates a quantity of 1 tablet, repackaged by RemedyRepack Inc. Directions advise seeing the package insert. Storage instructions specify 20-25°C with permitted excursions to 15-30°C. Manufacturer listed as Breckenridge, Boca Raton, FL.*

FDA Label Image

Remedy_label (Remedy Label)

Label for OXcarbazepine 150 mg film-coated tablets, quantity 30. The label includes the NDC number 70518-2253-00, manufacturer information for Breckenridge, Boca Raton, FL, and repackaging by RemedyRepack Inc. It also notes storage conditions and directs users to see the package insert for directions for use.*

FDA Label Image

Chemical Structure (Oxcarbazepine 01)

Chemical structure of oxcarbazepine, showing a dibenzazepine framework with a ketone group and an amide substituent attached to the nitrogen.*

FDA Label Image

Figure 1 (Oxcarbazepine 02)

A Kaplan-Meier survival curve graph showing exit rate over time in days for patients starting from Day 2 at 8 am to Day 11 at 8 am in a clinical trial. Two groups are compared: Oxcarbazepine treatment (solid line) and placebo (dotted line). The graph includes a log-rank test p-value of 0.0001 indicating statistical analysis. Exit rate values range from 0 to 1 on the vertical axis.*

FDA Label Image

Figure 2 (Oxcarbazepine 03)

A Kaplan-Meier curve showing seizure rate over days from the first dose to the first seizure for treatment groups taking Oxcarbazepine and placebo. The x-axis represents days, and the y-axis represents seizure rate. The plot includes a log-rank test p-value of 0.046 indicating statistical comparison between groups.*

FDA Label Image

Figure 3 (Oxcarbazepine 04)

A Kaplan-Meier curve showing the exit rate over time in days for two treatment groups labeled 'HIGH' (solid line) and 'LOW' (dotted line). The y-axis represents exit rate from 0.0 to 1.0, and the x-axis represents time to exit in days from 0 to 130. The log-rank test p-value is 0.0001, indicating statistical comparison between groups.*

FDA Label Image

Figure 4 (Oxcarbazepine 05)

A line graph showing exit rate versus time to exit in days for two treatment groups labeled HIGH and LOW. The HIGH group is represented by a solid line increasing gradually over time, while the LOW group is shown with a dotted line rising more steeply. A log-rank test p-value of 0.0001 is displayed indicating statistical significance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.